---
id: 2019-08-26--oklahoma-johnson-and-johnson-verdict
title: Oklahoma Wins $572 Million Verdict Against Johnson & Johnson for Opioid Public Nuisance
date: '2019-08-26'
importance: 8
actors:
  - Thad Balkman
  - Johnson & Johnson
  - State of Oklahoma
tags:
  - opioid-crisis
  - legal-accountability
  - public-nuisance
  - corporate-liability
  - state-lawsuits
status: confirmed
sources:
  - title: Johnson & Johnson Ordered To Pay $572 Million In Oklahoma Opioid Lawsuit
    url: https://www.npr.org/sections/health-shots/2019/08/26/754481268/judge-in-opioid-trial-rules-johnson-johnson-must-pay-oklahoma-572-million
    publisher: NPR
    date: '2019-08-26'
    tier: 1
  - title: Oklahoma wins $572 million from opioid manufacturer Johnson & Johnson
    url: https://stateimpact.npr.org/oklahoma/2019/08/28/oklahoma-wins-572-million-from-opioid-manufacturer-johnson-johnson/
    publisher: StateImpact Oklahoma
    date: '2019-08-28'
    tier: 1
  - title: Oklahoma judge finds Johnson & Johnson fueled opioid crisis
    url: https://www.statnews.com/2019/08/26/oklahoma-judge-finds-johnson-johnson-fueled-opioid-crisis/
    publisher: STAT News
    date: '2019-08-26'
    tier: 1
---

On August 26, 2019, Cleveland County District Judge Thad Balkman delivered a landmark $572 million judgment against pharmaceutical giant Johnson & Johnson for the company's role in fueling Oklahoma's opioid epidemic. The decision marked the first time a drugmaker was held culpable in court for the fallout from years of liberal opioid dispensing that began in the late 1990s.

## Landmark Public Nuisance Ruling

Judge Balkman's ruling affirmed the key legal argument of the state's case: that Johnson & Johnson had created a "public nuisance" through its "misleading marketing and promotion of opioids." The decision found that the company acted improperly by downplaying addiction risks and overstating benefits of opioid painkillers.

This public nuisance theory represented a novel legal approach to holding pharmaceutical companies accountable, applying a doctrine traditionally used for environmental contamination and property issues to the public health crisis caused by aggressive opioid marketing.

## $572 Million for One Year of Treatment

The $572 million award fell far short of the $17.5 billion Oklahoma requested to fund opioid treatment and prevention programs over 30 years. Judge Balkman's calculation provided funding for only a single year of Oklahoma's opioid abatement plan, which included:
- Opioid treatment programs
- Prevention screening
- Continuing medical education for prescribers
- Pain management programs
- Neonatal abstinence syndrome treatment for babies born addicted

The disparity between requested and awarded amounts highlighted the challenge of adequately compensating states for the multi-generational costs of the opioid epidemic.

## Subsequent Reduction to $465 Million

In November 2019, Judge Balkman reduced the financial penalty from $572 million to $465 million after correcting a mathematical error in the original calculation. Johnson & Johnson immediately announced it would appeal the decision, further delaying any funds reaching treatment programs.

## First Trial Verdict Against Pharmaceutical Company

This verdict represented the first trial judgment holding a pharmaceutical manufacturer liable for the opioid crisis. Previous cases against Purdue Pharma and others had been settled before trial. The Oklahoma decision demonstrated that pharmaceutical companies could be held accountable through litigation, even if they ultimately succeeded on appeal.

The trial established important legal precedent and created a record of evidence documenting pharmaceutical marketing practices, internal company knowledge of addiction risks, and the connection between marketing and prescribing patterns.

## Misleading Marketing Evidence

The trial revealed Johnson & Johnson's systematic efforts to downplay opioid risks:
- Marketing materials minimized addiction potential
- Sales representatives promoted opioids for chronic pain without adequate warnings
- Company-funded studies and medical education programs promoted aggressive prescribing
- Internal documents showed knowledge of addiction risks while external messaging denied them

## Pattern: Civil Liability Without Criminal Prosecution

While the $572 million (later $465 million) judgment represented significant civil liability, no Johnson & Johnson executives faced criminal charges despite evidence of knowingly misleading marketing. This continued the pattern established by Purdue's 2007 guilty plea: companies pay civil penalties or fines, but executives avoid personal criminal accountability.

## Limited Impact on National Crisis

Oklahoma's verdict, while symbolically important, did little to address the national opioid crisis:
- Funding covered only one year of treatment needs
- No criminal accountability for executives
- Decision subject to appeal, delaying payment
- No deterrent effect on other pharmaceutical companies
- Opioid deaths continued rising nationally

## Precedent for Future Litigation

The Oklahoma decision encouraged other states and local governments to pursue opioid litigation against pharmaceutical companies, distributors, and pharmacy chains. The public nuisance theory and evidence presented at trial provided templates for subsequent cases, leading to:
- November 2021: Ohio jury finding CVS, Walgreens, Walmart liable
- February 2022: $26 billion national settlement with distributors and J&J
- Multiple other state and local settlements

## Accountability Delayed

The August 2019 verdict came 23 years after OxyContin's 1996 launch and 12 years after Purdue's 2007 guilty plea. The multi-decade delay in holding pharmaceutical companies accountable through litigation demonstrates how corporate legal resources and complex legal processes allow companies to avoid consequences for years while crises escalate and deaths mount.

## Appeal and Eventual Overturn

Johnson & Johnson appealed the decision. In November 2021, the Oklahoma Supreme Court reversed the trial court's judgment, finding that the state's public nuisance law did not apply to the sale and marketing of prescription opioids. The reversal eliminated the $465 million judgment entirely, demonstrating how appellate processes can ultimately shield corporations from liability even after trial court findings of wrongdoing.

This case exemplifies both the potential and limitations of civil litigation as an accountability mechanism: trial courts may find liability and award damages, but appellate processes can take years and ultimately overturn even landmark verdicts, leaving victims without compensation and corporations without meaningful consequences.
